Last 28 quarters of trend data · Healthcare · Drug Discovery Platforms
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -22.04 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 30.91 | — | 4.51 | 18.82 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -80.3% | -30.8% | — | |
| P/S Ratio | 54.82 | 148.06 | 31.80 | 5.69 | 41.97 | 14.98 | 39.19 | 42.73 | 29.45 | 29.73 | 33.30 | 45.25 | 50.45 | 46.40 | 44.49 | 35.42 | 7.70 | 16.51 | 2.40 | 8.08 | 253.71 |
| — | +888.2% | -18.8% | -86.7% | +42.5% | -49.6% | +17.7% | -5.6% | -41.6% | -35.9% | -25.1% | +27.8% | +555.0% | +181.1% | +1755.2% | +338.3% | -97.0% | -69.5% | -82.1% | -47.9% | — | |
| P/B Ratio | 3.67 | 2.68 | 1.13 | 1.06 | 1.56 | 1.02 | 0.65 | 0.82 | 0.71 | 0.78 | 1.17 | 1.44 | 1.13 | 1.56 | 1.80 | 2.47 | 2.50 | 2.50 | 2.52 | 4.39 | 5.86 |
| — | +163.3% | +73.8% | +29.3% | +119.3% | +29.7% | -44.7% | -43.3% | -36.8% | -49.8% | -34.6% | -41.7% | -54.9% | -37.5% | -28.6% | -43.6% | -57.4% | -59.6% | -77.9% | -71.7% | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 41.06 | — | 3.15 | 8.86 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -73.8% | -65.5% | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 15.90 | — | 2.75 | 11.77 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -82.5% | -37.5% | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 17.72 | — | 2.75 | 11.38 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -82.6% | -41.7% | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.6% | 100.0% | -4.1% | 82.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 92.8% | 85.2% | 88.7% | 85.9% | 84.3% | 100.0% |
| — | 0.0% | -104.1% | -17.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +7.8% | +17.4% | +12.8% | +16.4% | +10.1% | -14.8% | +2.0% | -4.7% | — | 0.0% | |
| Operating Margin | -289.0% | -1550.0% | -691.7% | -63.7% | -851.8% | -290.2% | -1479.6% | -1440.7% | -1439.4% | -1276.2% | -551.5% | -719.6% | -831.8% | -511.0% | -532.1% | -175.3% | 37.2% | -18.3% | 71.1% | 58.5% | -510.1% |
| — | -434.1% | +53.2% | +95.6% | +40.8% | +77.3% | -168.3% | -100.2% | -73.1% | -149.7% | -3.6% | -310.4% | -2334.8% | -2694.8% | -848.8% | -399.6% | +107.3% | +28.1% | -8.9% | -24.3% | -2601.1% | |
| Net Margin | -194.9% | -1368.6% | -519.1% | -19.9% | -637.8% | -203.3% | -1077.2% | -677.4% | -785.4% | -504.3% | -408.0% | -513.7% | -433.6% | -303.6% | -329.0% | -138.7% | 26.3% | -14.8% | 53.2% | 43.0% | -388.2% |
| — | -573.3% | +51.8% | +97.1% | +18.8% | +59.7% | -164.0% | -31.9% | -81.2% | -66.1% | -24.0% | -270.2% | -1750.9% | -1954.5% | -717.8% | -422.5% | +106.8% | -75.8% | -7.9% | -23.5% | -1249.4% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -14.5% | -6.0% | -4.5% | -0.9% | -5.8% | -3.4% | -4.4% | -3.2% | -4.7% | -3.3% | -3.6% | -4.0% | -2.4% | -2.5% | -3.3% | -2.4% | 2.2% | -0.6% | 15.1% | 6.1% | -2.2% |
| — | -76.7% | -3.3% | +71.1% | -24.1% | -3.8% | -23.3% | +20.6% | -94.0% | -29.7% | -8.3% | -67.7% | -211.3% | -353.1% | -121.8% | -139.7% | +197.1% | -132.3% | +15.1% | -76.2% | +25.6% | |
| ROA | -10.8% | -4.2% | -3.2% | -0.7% | -4.1% | -2.5% | -3.4% | -2.5% | -3.6% | -2.6% | -2.8% | -3.1% | -1.9% | -2.0% | -2.6% | -1.9% | 1.7% | -0.4% | 11.6% | 4.8% | -1.8% |
| — | -67.6% | +3.9% | +73.5% | -13.7% | +1.5% | -22.6% | +20.9% | -94.2% | -27.7% | -4.3% | -62.6% | -210.9% | -372.3% | -122.8% | -140.2% | +192.0% | -109.1% | +5.4% | -76.4% | -1.6% | |
| ROIC | -16.7% | -4.9% | -4.4% | -2.1% | -5.5% | -3.7% | -5.0% | -5.5% | -6.8% | -6.6% | -3.8% | -4.5% | -3.8% | -3.5% | -4.8% | -3.0% | 4.0% | -1.1% | 26.1% | 11.6% | -6.3% |
| — | -31.6% | +12.2% | +61.0% | +19.4% | +43.6% | -31.0% | -21.2% | -81.6% | -89.0% | +21.2% | -50.5% | -193.9% | -223.4% | -118.4% | -126.0% | +164.1% | +48.7% | -41.2% | -88.1% | +95.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.14 | 0.07 | 0.06 | 0.07 | 0.06 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.06 | 0.03 | 0.03 | 0.04 | 0.03 |
| — | +7.3% | +125.3% | +139.3% | +122.8% | +117.5% | +1.8% | -7.8% | -3.0% | -7.8% | -5.3% | +0.7% | +12.2% | +131.9% | +106.2% | +70.8% | +93.1% | -11.7% | +64.5% | +378.6% | -52.4% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.71 | — | 0.18 | 0.46 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +46.3% | +1017.6% | — | |
| Current Ratio | 11.32 | 12.77 | 14.05 | 11.32 | 10.10 | 11.07 | 10.15 | 9.81 | 9.34 | 10.96 | 7.76 | 7.33 | 8.34 | 7.83 | 10.50 | 8.67 | 9.86 | 5.17 | 5.50 | 7.70 | 16.22 |
| — | +15.3% | +38.5% | +15.5% | +8.2% | +1.0% | +30.7% | +33.9% | +11.9% | +40.1% | -26.1% | -15.5% | -15.4% | +51.3% | +90.8% | +12.5% | -39.2% | -58.2% | -46.4% | -2.0% | +186.1% | |
| Quick Ratio | 11.23 | 12.63 | 13.89 | 11.23 | 10.10 | 11.07 | 10.15 | 9.81 | 9.34 | 10.96 | 7.75 | 7.32 | 8.33 | 7.82 | 10.48 | 8.65 | 9.62 | 5.06 | 5.39 | 7.69 | 16.19 |
| — | +14.0% | +36.9% | +14.5% | +8.2% | +1.0% | +30.9% | +34.0% | +12.1% | +40.3% | -26.0% | -15.4% | -13.4% | +54.5% | +94.7% | +12.5% | -40.6% | -59.1% | -47.5% | -2.0% | +188.2% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 28 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ABCL stock.
AbCellera Biologics Inc.'s current P/E is -22.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
AbCellera Biologics Inc.'s current operating margin is -289.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking AbCellera Biologics Inc.'s business trajectory between earnings reports.